Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Xalatan · 1 trial · 2 indications
Value at Week 8 minus value at baseline
| Arm | Type | Description |
|---|---|---|
| Xalatan | EXPERIMENTAL | - |
| Xalacom | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Xalatan | DRUG | latanoprost 0.005%, one rop once daily in evening |
| Xalacom | DRUG | latanoprost 0.005% adn timolol 0.5%, one drop, once daily |
Inclusion Criteria: * Intraocular pressure is 18 mmHg or more at baseline after treatment with Xalatan for 4 weeks or more. Exclusion Criteria: * History of no-response to timolol * History of trabeculectomy * History of other ocular surgery including ALT, SLT,and trabeculotomy within 6 months
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Glaukos Corp | GKOS | 6 | PHASE3 | Gen 2 Travoprost Intracameral, Timolol eye 0.5% |
| AbbVie, Inc. | ABBV | 2 | PHASE3 | Undisclosed |
| SpyGlass Pharma, Inc. | SGP | 4 | PHASE3 | Bimatoprost System, Timolol, 0.5% |
| Amneal Pharmaceuticals, Inc. Class A | AMRX | 2 | PHASE3 | Test- Bimatoprost 0.01%, Reference- LUMIGAN |
| Alcon AG | ALC | 5 | N/A | Undisclosed |
| Sight Sciences, Inc. | SGHT | 3 | N/A | Undisclosed |
Xalatan is a small molecule used for the treatment of glaucoma, specifically studied in patients with primary open angle glaucoma (POAG) or ocular hypertension. It is an ophthalmic medication developed by Pfizer, Inc. (NYSE: PFE) and is currently in Phase 3 clinical development.
Xalatan is developed by Pfizer, Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol PFE. The drug is being studied for the treatment of glaucoma and ocular hypertension.
Xalatan is in Phase 3 clinical development. It has completed one Phase 3 trial, which was a randomized, double-blind, controlled study involving 300 participants. The drug is investigational and not yet approved for commercial use.
Xalatan has one completed Phase 3 clinical trial, identified as NCT00383019. This study compared Xalacom and Xalatan in patients with primary open angle glaucoma (POAG) or ocular hypertension. The trial enrolled 300 participants in Japan, with a minimum age of 20 years.
Xalatan and Xalacom are different medications, as they were compared against each other in a clinical trial. The Phase 3 study NCT00383019 was designed to compare the two treatments in patients with primary open angle glaucoma or ocular hypertension, indicating they are distinct products.